Stay up-to-date with stories, interviews, event information and the latest announcements from your favorite travel brands. Find the latest hotspots and those 'never been done before' experiences along with tips and recommendations from VAX advisors.

May 19, 2021 · X-Vax Technology is ready to submit an IND application to the U.S. FDA for its experimental herpes vaccine against HSV-1 and -2. Here's what you need to know.

Operator of a biotechnology company intended to develop vaccines against pathogens acquired by a mucosal infection.

Aug 14, 2023 · Herpes simplex viruses (HSV) cause chronic infections with significant morbidity. Prior vaccines, designed to generate neutralizing antibodies (nAbs) targeting glycoprotein D (gD), failed to provide durable protection. We adopted a different strategy and evaluated a single-cycle virus deleted in gD (ΔgD-2).

May 18, 2021 · An inside look at preclinical stage biotech, X-VAX, which is preparing to engage the FDA with data on an HSV vaccine candidate that could have therapeutic impact on a virus carried by the majority of the world’s population.

Jul 21, 2021 · PALM BEACH GARDENS, Fla., July 21, 2021 /PRNewswire/ -- X-Vax Technology, Inc. (X-VAX ®), a biotechnology company developing vaccines based on a new approach that mediates the killing of...

JUPITER, Fla., July 23, 2019 /PRNewswire/ -- X-Vax Technology, Inc. (X-VAX ™), a biotechnology company developing vaccines based on a new approach that mediates the killing of infected...

X-Vax Technology is a biotechnology company focused on the preclinical and clinical development of vaccines against pathogens that cause mucosal infections such as herpes, influenza, tuberculosis and HIV, affecting hundreds of millions of people around the globe.

Jul 23, 2019 · X-Vax Technology, Inc. (X-VAX ™), a biotechnology company developing vaccines based on a new approach that mediates the killing of infected cells, today announced that it has raised $56 million in an upsized Series A financing with participation from strategic and institutional investors, including Johnson & Johnson Innovation

Oct 3, 2019 · Veering from the field’s focus on neutralizing antibodies, X-Vax is developing vaccines that elicit non-neutralizing antibodies that direct the immune system to kill infected cells. Its lead candidate is in preclinical development to prevent HSV infection.